FDA Expands Approval of Intranasal Esketamine Therapy (Spravato)
Shyam Tailor
Written by Joao L. de Quevedo, MD, PhD In a significant step forward for mental health care, the U.S. Food and Drug Administration (FDA) has expanded its approval of Spravato (esketamine) nasal spray. Initially approved in 2019 for treatment-resistant depression,... The post FDA Expands Approval of Intranasal Esketamine Therapy (Spravato) appeared first on Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences .